Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Plasma cell 1Lymphoid 1Classical hematology 1

Conditions

Hematologic Neoplasms 3Neoplasms, Plasma Cell 2Lymphoma 2Leukemia 2Infections 2Waldenstrom Macroglobulinemia 1Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Recurrence 1Pulmonary Arterial Hypertension 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pancreatic Neoplasms 1Pancreatic Diseases 1Pain 1Other Infectious Diseases 1Neutropenia 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Migraine Disorders 1

Interventions

Cyclophosphamide 32Tacrolimus 29fludarabine 27Mycophenolic Acid 23fludarabine phosphate 22Busulfan 19Whole-Body Irradiation 18Melphalan 16Methotrexate 15Antilymphocyte Serum 14Rituximab 12Bortezomib 11Stem Cell Transplantation 10Cyclosporine 10thymoglobulin 9Sirolimus 9Granulocyte Colony-Stimulating Factor 9Peripheral Blood Stem Cell Transplantation 8Thiotepa 7Interviews as Topic 7Filgrastim 7Dexamethasone 7Clofarabine 7Blood Specimen Collection 6Alemtuzumab 6merphos 5Voriconazole 5Standard of Care 5Nivolumab 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Hematologic Neoplasms × Piperacillin, Tazobactam Drug Combination × Clear all
NCT04983901 2026-04-06

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 38 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT00044759 2007-10-10

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡